leadf
logo-loader
viewXPhyto Therapeutics Corp.
(
CSE:XPHYOTCQB:XPHYF
)

XPhyto Therapeutics partner 3A revives grant from German Ministry of Education and research

XPhyto (CSE: XPHY- OTC: XPHYF) CEO Hugh Rogers joined Steve Darling from Proactive Vancouver to bring news their German partner 3aDiagnostics and their contract research collaborators, have received a grant from the German Federal Ministry of Education and Research.

Roger telling Proactive how much that is grant is for and how they plan to use that capital as they continue to develop a pathogen-specific biosensor put into XPhyto’s dissolvable thin-film platform.

Quick facts: XPhyto Therapeutics Corp.

Follow
CSE:XPHY

Price: 1.4 CAD

Market Cap: $97.67 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

XPhyto Therapeutics takes a major step forward launching first commercial...

XPhyto Therapeutics CEO Hugh Rogers joined Steve Darling from Proactive to share details the company and their partner 3a-diagnostics have successfully registered their first biosensor test in oral inflammation with the German authorities. Rogers telling Proactive this will be an at-home...

3 weeks, 1 day ago

2 min read